A critical analysis of prognostic factors in North American patients with human T‐cell lymphotropic virus type‐1‐associated adult T‐cell leukemia/lymphoma

To define the clinicopathologic and prognostic features of patients with human T‐cell lymphotropic virus type‐1 (HTLV‐1)‐associated adult T‐cell leukemia/lymphoma (ATLL) in North America, standard criteria were used to identify patients with ATLL.

[1]  A. Bazarbachi,et al.  Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Yamaguchi,et al.  Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Harrington,et al.  A Worldwide Meta-Analysis on the Use of Zidovudine and Interferon-alpha for the Treatment of Adult T–Cell Leukemia/Lymphoma. , 2007 .

[4]  M. Tomonaga,et al.  Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). , 2007, Leukemia research.

[5]  S. Iida,et al.  Regulatory T‐cell function of adult T‐cell leukemia/lymphoma cells , 2007, International journal of cancer.

[6]  H. Hasegawa,et al.  [Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy]. , 2006, Gan to kagaku ryoho. Cancer & chemotherapy.

[7]  B. Blumenstein.  A comment on the utility of recursive partitioning. , 2005, Journal of Clinical Oncology.

[8]  N. Mueller,et al.  Persistent paradox of natural history of human T lymphotropic virus type I: parallel analyses of Japanese and Jamaican carriers. , 2004, The Journal of infectious diseases.

[9]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[10]  J. Cavenagh,et al.  Interferon α and zidovudine therapy in adult T‐cell leukaemia lymphoma: response and outcome in 15 patients , 2001, British journal of haematology.

[11]  M. Tomonaga,et al.  A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303 , 2001, British journal of haematology.

[12]  G. Hale,et al.  The CD52 antigen and development of the CAMPATH antibodies. , 2001, Cytotherapy.

[13]  T. Waldmann,et al.  The Combination of Zidovudine and Interferon AIpha-2B in the Treatment of Adult T-Cell Leukemia/Lymphoma , 2001, Leukemia & lymphoma.

[14]  M. Tomonaga,et al.  Adult T‐cell leukemia cells over‐express the multidrug‐resistance‐protein (MRP) and lung‐resistance‐protein (LRP) genes , 1999, International journal of cancer.

[15]  M. Tomonaga,et al.  Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immunophenotype and defective HTLV‐1 genotype , 1999, British journal of haematology.

[16]  A. Bazarbachi,et al.  Treatment of HTLV-1 associated adult T-cell leukemia lymphoma with a combination of Zidovudine and alpha interferon. Report of the French experience , 1999 .

[17]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Catovsky,et al.  Clinical and laboratory features of adult T-cell leukaemia lymphoma in Barbados. , 1996, Leukemia & lymphoma.

[19]  M. Tomonaga,et al.  An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[20]  G. Mufti,et al.  Adult T-cell leukemia/lymphoma in London: clinical experience of 21 cases. , 1996, Leukemia & lymphoma.

[21]  M. Kaplan,et al.  Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. , 1995, The New England journal of medicine.

[22]  E. Macintyre,et al.  Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa , 1995 .

[23]  W. Blattner,et al.  Adult T‐Cell leukemia/lymphoma: A working point‐score classification for epidemiological studies , 1994, International journal of cancer.

[24]  P. Hartge,et al.  Role of HTLV-I in development of non-Hodgkin lymphoma in Jamaica and Trinidad and Tobago , 1993, The Lancet.

[25]  K. Nabeshima,et al.  Autopsy findings in 47 cases of adult T-cell leukemia/lymphoma in Miyazaki prefecture, Japan. , 1993, Leukemia & lymphoma.

[26]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[27]  H. Koeffler,et al.  Mutations of the p53 gene in adult T-cell leukemia. , 1992, Blood.

[28]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[29]  K. Uozumi,et al.  Expression of P-glycoprotein in adult T-cell leukemia cells. , 1990, Blood.

[30]  K. Tajima.  The 4th nation‐wide study of adult T‐cell leukemia/lymphoma (ATL) in Japan: Estimates of risk of ATL and its geographical and clinical features , 1990, International journal of cancer.

[31]  K. Akashi,et al.  Central nervous system involvement in adult T‐cell leukemia/lymphoma , 1990, Cancer.

[32]  K. Arai,et al.  ATL‐derived factor (ADF), an IL‐2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol‐reduction in the IL‐2 receptor induction. , 1989, The EMBO journal.

[33]  M. Greaves,et al.  ADULT T-CELL LYMPHOMA-LEUKAEMIA IN BLACKS FROM THE WEST INDIES , 1982, The Lancet.

[34]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[35]  D. Watkin,et al.  POSTOPERATIVE WOUND INFECTION. , 1965, Lancet.

[36]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[37]  A. Bazarbachi,et al.  A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. , 2002, The hematology journal : the official journal of the European Haematology Association.

[38]  B. Hanchard.  Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[39]  Berthold Lausen,et al.  Maximally selected rank statistics , 1992 .

[40]  Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Lymphoma Study Group (1984-1987). , 1991, Leukemia research.

[41]  S. Neely.  Adult T-cell leukemia-lymphoma. , 1989, The Western journal of medicine.

[42]  D.,et al.  Regression Models and Life-Tables , 2022 .